Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

I made a mistake in my post the other day but my numbers are much closer to BK's than George's. There's a lot of overlap with the article I linked (linked again below) and BK's reference. Both articles are relatively recent (2008, 2009) and obviously, BK's discusses the many considerations for dose conversion in greater detail. Both articles discuss erroneous resveratrol calculations and provide the same correct calculation.

Dose translation revisited

I made a mistake in my last post and inadvertently plugged in 350 mg where I should have used 200 mg. Here is my corrected calculation:

Redoing the math for Cohort 9 using the forumulas from the above reference:

Cohort 9 dose is 350 mg/m2 (intravenous)
Mouse dose dramatically slowing tumor growth was 200 mg/kg (intraperitoneal)

Human Equivalent Dose in mg/kg= Animal dose (mg/kg) * Animal Km/ Human Km

HED Kevetrin= 200mg/kg * 3/37
= 16.21 mg/kg

Conversion of Cohort 9 dose from mg/m2 to mg/kg:
Cohort 9 Kevetrin= 350 mg/m2/37 = 9.46 mg/kg

So Cohort 9 Intravenous dose is 9.46 mg/kg. This dose is roughly equivalent to 0.58 the INTRAPERITONEAL dose of 16.21 mg/kg used in the mouse study. Intraperitoneal dosing will result in lower peak serum levels than intravenous dosing with the same dose. I do not know the correlation coefficient for Kevetrin IP/IV but even if it is close to 1.0, twice a week dosing at Cohort 9 levels are likely to yield serum levels comparable to the highly effective 200 mg/kg intraperitoneal mouse dosing.

Also, these calculations are reasonably consistent with BK's HED efficacy range of 310-620mg/m2.

Though I can plug in numbers to formulas for the conversion, I very much believe Dr. Menon has a greater depth of understanding of the complexities of conversions than me. I do find it reassuring that BK and I can take somewhat different approaches and arrive at similar conclusions.